Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter, SimplicityBio Plan to Offer Biomarker Discovery Products

NEW YORK (GenomeWeb) – Sweden's Tataa Biocenter announced today that it has partnered with in silico solutions provider SimplicityBio to market products for biomarker discovery, signature optimization, and validation on a variety of platforms.

The partners will combine their products to offer a complete solution for biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation, with the goal of developing diagnostics, prognostics, and theranostics based on reliable biomarker signatures. Platforms include microarrays, qPCR, dPCR, and next-generation sequencing, and almost any kind of biomarker with an emphasis on mRNA, microRNA, lncRNA, SNPs, CNVs, methylation markers, cfDNA, proteins, and circulating tumor cells.

Further terms of the deal were not disclosed.

Matthew Hall, CSO of Monthey, Switzerland-based SimplicityBio, said in a statement that Tataa's ability to generate genomic data based on its analysis pipelines is ideal for SimplicityBio's biomarker discovery and modeling pipelines.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.